By Stephen Nakrosis
Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis.
After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52.
The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors.
AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 03, 2025 18:10 ET (22:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.